Nothing Special   »   [go: up one dir, main page]

ATE234838T1 - Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften - Google Patents

Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften

Info

Publication number
ATE234838T1
ATE234838T1 AT96941088T AT96941088T ATE234838T1 AT E234838 T1 ATE234838 T1 AT E234838T1 AT 96941088 T AT96941088 T AT 96941088T AT 96941088 T AT96941088 T AT 96941088T AT E234838 T1 ATE234838 T1 AT E234838T1
Authority
AT
Austria
Prior art keywords
purine derivatives
antipoliferative
rnh
cyclin
effect
Prior art date
Application number
AT96941088T
Other languages
English (en)
Inventor
Laurent Meijer
Emile Bisagni
Michel Legraverend
Miroslav Strnad
Original Assignee
Centre Nat Rech Scient
Inst Botan Experimentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Botan Experimentale filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE234838T1 publication Critical patent/ATE234838T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT96941088T 1995-12-01 1996-11-29 Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften ATE234838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514237A FR2741881B1 (fr) 1995-12-01 1995-12-01 Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
PCT/FR1996/001905 WO1997020842A1 (fr) 1995-12-01 1996-11-29 Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques

Publications (1)

Publication Number Publication Date
ATE234838T1 true ATE234838T1 (de) 2003-04-15

Family

ID=9485066

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96941088T ATE234838T1 (de) 1995-12-01 1996-11-29 Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften
AT02293256T ATE500255T1 (de) 1995-12-01 1996-11-29 Purin-derivat zur anwendung in der behandlung einer proliferativen erkrankung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02293256T ATE500255T1 (de) 1995-12-01 1996-11-29 Purin-derivat zur anwendung in der behandlung einer proliferativen erkrankung

Country Status (11)

Country Link
US (6) US6316456B1 (de)
EP (2) EP1308447B1 (de)
JP (1) JP4340796B2 (de)
AT (2) ATE234838T1 (de)
CA (1) CA2238843C (de)
DE (2) DE69638337D1 (de)
DK (2) DK0874847T3 (de)
ES (2) ES2195027T3 (de)
FR (1) FR2741881B1 (de)
PT (2) PT874847E (de)
WO (1) WO1997020842A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69627195T2 (de) 1995-11-01 2004-01-29 Novartis Ag Purinderivate und verfahren zu ihrer herstellung
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CA2287531A1 (en) * 1997-03-03 1998-09-11 Board Of Regents, The University Of Texas System Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
EP1003746A1 (de) * 1997-08-07 2000-05-31 The Regents Of The University Of California Purin inhibitoren der protein kinasen, g proteine und polymerasen
JP2001515722A (ja) * 1997-09-05 2001-09-25 クロップデザイン エヌ．ブイ． 植物細胞周期蛋白質を調節する方法および手段ならびに植物細胞増殖の制御におけるそれらの使用
US7265267B1 (en) 1997-09-16 2007-09-04 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
AU754803B2 (en) * 1997-09-16 2002-11-28 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
US6710227B1 (en) 1998-09-16 2004-03-23 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
EP0911634A1 (de) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmazeutische Verwendungen von Regulatoren der CDK-2
CA2307171A1 (en) * 1997-10-24 1999-05-06 Cropdesign N.V. A novel mitogenic cyclin and uses thereof
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
PT1056744E (pt) * 1998-02-26 2004-03-31 Aventis Pharma Inc 2-¬trans-(4-aminociclo-hexil)amino|purinas 6,9-dissubstituidas
CN1128149C (zh) * 1998-02-26 2003-11-19 阿旺蒂斯制药公司 6,9－二取代的2－[反－(4－氨基环己基)氨基]嘌呤
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6703395B2 (en) * 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US6221873B1 (en) * 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6664439B1 (en) 1998-04-28 2003-12-16 The Procter & Gamble Company Absorbent articles with distribution materials positioned underneath storage material
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
AU1559400A (en) * 1998-12-04 2000-06-26 Cropdesign N.V. Method to identify regulators of cdk activity
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
DK1150982T3 (da) * 1999-02-01 2005-12-27 Cv Therapeutics Inc Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa
AU2004200192B2 (en) * 1999-02-01 2006-11-16 Gilead Palo Alto, Inc. Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
EP1026251A3 (de) * 1999-02-03 2000-09-06 Pfizer Products Inc. Transgene Tiere welche das menschliche p25 Gen exprimieren
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
WO2001055148A1 (en) * 2000-01-27 2001-08-02 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US20040254094A1 (en) * 2000-10-11 2004-12-16 The Trustees Of University Of Pennsylvania And Board Of Regents Suppression of cyclin kinase activity for prevention and treatment of infections
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6667311B2 (en) 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US7176312B2 (en) * 2001-10-12 2007-02-13 The Scripps Research Institute Kinase inhibitor scaffolds and methods for their preparation
US20050222054A1 (en) * 2002-03-27 2005-10-06 Cyclacel Limited Combination comprising a CDK inhibitor and doxorubicin
CA2488562A1 (en) * 2002-06-27 2004-01-08 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
US20050226879A1 (en) * 2002-09-17 2005-10-13 Ulmann Katharine S Methods and compositions related to inhibiting nuclear envelope breakdown
AU2003276467A1 (en) * 2002-11-06 2004-06-07 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
MXPA05004920A (es) * 2002-11-06 2005-08-18 Cyclacel Ltd Combinacion que comprende un inhibidor cdk y cisplatin.
GB0225873D0 (en) * 2002-11-06 2002-12-11 Cyclacel Ltd Combination
ATE409484T1 (de) * 2002-12-17 2008-10-15 Centre Nat Rech Scient Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1444982A1 (de) * 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
GB0307640D0 (en) * 2003-04-02 2003-05-07 Cyclacel Ltd Markers
GB0315259D0 (en) * 2003-06-30 2003-08-06 Cyclacel Ltd Use
US20070287718A1 (en) * 2003-11-06 2007-12-13 Green Simon R Methods for the Treatment of Multiple Myeloma Using Roscovitine
EP2277595A3 (de) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Verbindungen zur Immunopotenzierung
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
WO2006040036A1 (en) 2004-10-13 2006-04-20 F. Hoffmann-La Roche Ag Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
FR2876583B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
KR20110010813A (ko) * 2005-10-14 2011-02-07 에프. 호프만-라 로슈 아게 5-(2-클로로페닐)-1,2-디히드로-7-플루오로-8-메톡시-3-메틸-피라졸로[3,4-ｂ][1,4] 벤조디아제핀의 투여 섭생
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
JP5486808B2 (ja) 2005-11-30 2014-05-07 アッヴィ・インコーポレイテッド アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
EP2289909B1 (de) 2005-11-30 2014-10-29 AbbVie Inc. Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (de) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmazeutische kombinationen
DK2076268T3 (da) * 2006-10-19 2013-04-22 Genzyme Corp Roscovitin til behandling af visse cystiske sygdomme
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
EP2142545A1 (de) 2007-03-28 2010-01-13 NeuroSearch A/S Purinylderivate und ihre verwendung als kaliumkanalmodulatoren
NZ579248A (en) * 2007-03-28 2011-08-26 Neurosearch As Purinyl derivatives and their use as potassium channel modulators
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
CZ300774B6 (cs) * 2007-10-05 2009-08-05 Univerzita Palackého Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny
BRPI0820722A2 (pt) 2007-12-20 2015-06-16 Novartis Ag Derivados de tiazol usados como inibidores de pi 3 cinases
JP2011207764A (ja) * 2008-07-29 2011-10-20 Univ Of Tokyo Ｃｄｋ阻害剤によるｃ型肝炎ウイルスの複製抑制
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
CZ302623B6 (cs) * 2009-04-22 2011-08-03 Univerzita Palackého Oxalátokomplexy platiny s deriváty N6-benzyladeninu, zpusob jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
FR2945747A1 (fr) 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
ES2611885T3 (es) 2011-01-31 2017-05-11 Novartis Ag Derivados heterocíclicos novedosos
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
EP2561867A1 (de) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9-Hemmer zur Behandlung eines Mittellinienkarzinoms
EP2562265A1 (de) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Empfindlichkeit auf selektive CDK9-Inhibitoren
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
EP2874631A1 (de) 2012-05-15 2015-05-27 Cyclacel Limited Dosierungsschema für sapacitabin und seliciclib
JP6381523B2 (ja) 2012-05-16 2018-08-29 ノバルティス アーゲー Ｐｉ−３キナーゼ阻害剤の投与レジメン
MX2014014872A (es) 2012-06-26 2015-08-06 Saniona Aps Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
HUE057092T2 (hu) 2013-12-06 2022-04-28 Novartis Ag Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje
EP2907514B1 (de) 2014-02-17 2019-10-23 Manros Therapeutics Purinderivatverbindungen zur medizinischen Verwendung
US10555931B2 (en) 2014-05-28 2020-02-11 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US10729692B2 (en) * 2017-02-26 2020-08-04 Institute For Cancer Research Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
EP3606536A4 (de) * 2017-04-04 2020-12-16 University of Miami Biomarker für prostatakrebs und behandlung davon
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN112794852B (zh) * 2021-01-12 2021-11-30 江汉大学 一种含硒有机化合物及其制备方法与应用
CN112794853B (zh) * 2021-01-12 2021-11-30 江汉大学 一种有机硒化合物及其制备方法与应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844577A (en) * 1958-07-22 Certificate of correction
US2691654A (en) * 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US2830053A (en) * 1955-03-25 1958-04-08 Burroughs Wellcome Co 6-substituted purine compounds and method of making
US2966488A (en) * 1956-07-30 1960-12-27 Shive William Substituted alkylaminopurines
US3213095A (en) * 1963-04-04 1965-10-19 American Cyanamid Co N-benzylation of adenine
US3930005A (en) * 1973-06-15 1975-12-30 Squibb & Sons Inc Antiinflammatory agents and their use
US3862189A (en) * 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
DE2355536A1 (de) * 1973-11-07 1975-05-22 Merck Patent Gmbh Adeninderivate und verfahren zu ihrer herstellung
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
DE2550000A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Neue purin-derivate und verfahren zu ihrer herstellung
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4189485A (en) * 1977-08-23 1980-02-19 Takeda Chemical Industries, Ltd. Purine derivatives
DE2804416A1 (de) * 1978-02-02 1979-08-09 Boehringer Mannheim Gmbh Neue purin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
EP0363320A3 (de) * 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
DE69627195T2 (de) 1995-11-01 2004-01-29 Novartis Ag Purinderivate und verfahren zu ihrer herstellung
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
EP1003746A1 (de) * 1997-08-07 2000-05-31 The Regents Of The University Of California Purin inhibitoren der protein kinasen, g proteine und polymerasen
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
CA2488562A1 (en) * 2002-06-27 2004-01-08 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
US7960397B2 (en) * 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions

Also Published As

Publication number Publication date
CA2238843C (fr) 2012-04-10
US20090030019A1 (en) 2009-01-29
EP0874847B1 (de) 2003-03-19
US20100273802A1 (en) 2010-10-28
CA2238843A1 (fr) 1997-06-12
EP1308447A1 (de) 2003-05-07
US20020049218A1 (en) 2002-04-25
ES2364722T3 (es) 2011-09-13
DE69626855T2 (de) 2003-12-24
US20030186999A1 (en) 2003-10-02
PT874847E (pt) 2003-08-29
US6316456B1 (en) 2001-11-13
EP0874847A1 (de) 1998-11-04
US8163762B2 (en) 2012-04-24
PT1308447E (pt) 2011-06-07
FR2741881A1 (fr) 1997-06-06
DK1308447T3 (da) 2011-06-20
FR2741881B1 (fr) 1999-07-30
EP1308447B1 (de) 2011-03-02
JP2000501408A (ja) 2000-02-08
US20040235868A1 (en) 2004-11-25
WO1997020842A1 (fr) 1997-06-12
DK0874847T3 (da) 2003-07-14
ES2195027T3 (es) 2003-12-01
JP4340796B2 (ja) 2009-10-07
DE69626855D1 (de) 2003-04-24
DE69638337D1 (de) 2011-04-14
ATE500255T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
ATE234838T1 (de) Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften
DE60040905D1 (de) VERFAHREN ZUR HERSTELLUNG VON (E)-(6-i2-i4-(4-FLUORPHENYL)-6-ISOPROPYL-2-iMETHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL VINYL (4R,6S)-2,2-DIMETHYLi1,3 DIOXAN-4-YL)ESSIGSÄURE-TERT-BUTYLESTER
ATE415394T1 (de) Zwischeprodukte zur herstellung von retroviralen protease-hemmern
FI954874A (fi) Amino(tio)eetterijohdannaisia
ATE218555T1 (de) Octacylodepsideptide mit endoparasitizider wirkung
DK0657458T3 (da) Inhibitorer af proteinkinase-C
DE69232907D1 (de) Neue heterocyclische/cyclische amine
DE69526956D1 (de) Proteinkinase c-inhibitoren zur behandlung von neurologischen erkrankungen
DE59309819D1 (de) Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten zur Behandlung von Erkrankungen, die durch die nichtenzymatische Glykosylierung bedingt sind
IL98110A0 (en) N-(3-fluoro-2-phosphonylmethoxypropyl)derivatives of purine and pyrimidine heterocyclic bases,their preparation and use
PT1362045E (pt) Derivados de imidazole 2-tio substituidos e seu uso na industria farmaceutica
DE69927251D1 (de) Verfahren zur herstellung von purinderivaten und dessen zwischenprodukte
ATA152093A (de) Neue guanidin- und amidinsalze von 7-amino-3-hydroxymethyl-3-cephem-4-carbonsäure
DE59402263D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolid-2-onen
DE69830866D1 (de) Verfahren zur Herstellung von Nitroguanidin-Derivaten ausgehend von 2-Nitroimino-hexahydro-1,3,5-triazinen in Anwesenheit von Ammoniak, primärem oder sekundärem Amin
FI930367A (fi) Puridinderivat
DK422688A (da) Substituerede pyridylethanolaminer og fysiologisk acceptable salte og n-oxider deraf, deres fremstilling og anvendelse samt mellemprodukter og disses fremstilling
DK0535104T3 (da) Heterocyliske forbindelser deres fremstilling og anvendelse
DE59008523D1 (de) Verfahren zur Herstellung von Sulfonylharnstoff-Salzen und ihre Verwendung als Herbizide.
DK0381114T3 (da) Exo-3,4-O-benzyliden-3"-demethylchartreusin og salte deraf
ATE111093T1 (de) Verfahren zur herstellung von enantiomeren von 3- aminchromanderivaten.
ATE199556T1 (de) Verfahren zur fraktionierung von deacylierten glycerophospholipiden
DE59303525D1 (de) Verfahren zur Herstellung von N-(2-Hydroxypropyl)-2,6-dimethylmorpholin
DE69331305D1 (de) Zwischenprodukte und Verfahren zur Herstellung von 5,6-Dihydropyrrolo[2,3-d]pyrimidinen
DE59306969D1 (de) Verfahren zur Herstellung von N-(2-Sulfatoethyl)piperazin hoher Reinheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0874847

Country of ref document: EP